Fenofibrate

2 - [4 - (4- chlorobenzoyl ) phenoxy ]-2- methylpropionsäureisopropylester (IUPAC)

C10AB05

White to off- white crystalline powder

Fibrates

80-81 ° C ( crystals from 2-propanol )

Practically insoluble in water, sparingly soluble in methanol and ethanol, soluble in acetone, diethyl ether, benzene, and in chloroform

Attention

1600 mg · kg -1 ( LD50, mouse, oral)

Template: Infobox chemical / molecular formula search available

Fenofibrate is a drug from the group of fibrates ( Fibrinsäuren and their derivatives) and is used to treat primary and secondary hyperlipoproteinemia ( as in hypercholesterolemia and hypertriglyceridemia ) related. Fenofibrate - Lipanthyl ® - 1972 as a lipid -lowering drug from Fournier Pharma (now Abbott Laboratories) patented and is available as a generic in the trade.

Pharmacological properties

By influencing transcription factors on the PPAR receptor, the activity of lipoprotein lipase is increased in the periphery, whereby the plasma concentration of triglycerides and LDL is lowered, the concentration of HDL ( colloquially, the " good cholesterol " ), however, increases.

Studies (FIELD 2007 ACCORD 2008) showed independent of lipid levels in diabetic retinopathy slowing the progression and reduced the need for laser photocoagulation. In Australia, fenofibrate was approved drug legally for this indication.

With a half -life of up to 21 hours and a plasma protein binding of 99%, it is the longest effective fibrate. Possible side effects include nausea, vomiting, ventricular arrhythmia, increase in liver enzymes ( AST / ALT), and rarely myalgia and rhabdomyolysis (especially in combination with statins ). Contraindications include pregnancy and lactation, primary biliary cirrhosis, and the use of statins.

Trade names

Fenoglide, Lepanthyl, Lipofen, Lofibra, Procetofen, Secalip Supra ( Spain), Tricor, Triglide